Medical/Pharmaceuticals

ACROBiosystems Wins CiteAb Award, Gaining Worldwide Recognition

SAN DIEGO and NEWARK, Del., April 28, 2026 /PRNewswire/ -- Recently, ACROBiosystems was honored as a "Protein Supplier to Watch in Cancer Research in 2026" at the CiteAb Awards. CiteAb accelerates scientific research by providing a search engine and data services, and its awards leverage high-qu...

2026-04-28 23:00 3475

Natural Field Releases Research Findings on NFTriSolve® Co-Loading Liposome Formula

XI'AN, China, April 28, 2026 /PRNewswire/ -- Natural Field announced that the latest research and development breakthrough of the NFTriSolve® co-loading liposome technology has been achieved. Through a comparison of different formulations and processes in a zebrafish experiment, the research resu...

2026-04-28 22:59 4315

Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution

SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total revenue of RMB 10,073 million, representing a ...

2026-04-28 22:54 5938

ACROBiosystems Showcases AI-Driven Innovation at AACR 2026, Empowering Next-Generation Biologics Discovery

SAN DIEGO and NEWARK, N.J., April 28, 2026 /PRNewswire/ -- From April 17 to 22, 2026, ACROBiosystems—a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries—presented its comprehensive, AI‑driven protein solutions at the American Association for Cancer...

2026-04-28 22:00 4408

C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu-64)

DMF No. 43568 is now active and available for reference in global IND and NDA submissions CHENGDU, China, April 28, 2026 /PRNewswire/ -- C-Ray Therapeutics (Chengdu) Co., Ltd., today announced that its Type II Drug Master File (DMF) for COPPER [64Cu] CHLORIDE FOR RADIOLABELLING has been listed a...

2026-04-28 21:11 2770

Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer

SINGAPORE, PARIS and PHILADELPHIA, April 28, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company developing novel therapies for patients suffering from life-threatening cardiomyopathies, today announced the appointment of Monica Shah, MD, FACC, as Chief Medical Officer. Dr. Shah...

2026-04-28 21:05 3363

World's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical

CHONGQING, China, April 28, 2026 /PRNewswire/ -- Chongqing Claruvis Pharmaceutical Co., Ltd. recently announced that the China's National Medical Products Administration (NMPA) has approved its Retoxin® (recombinant botulinum toxin type A, project code YY001) for the temporary improvement of mod...

2026-04-28 20:38 3665

HoneyNaps Expands into Boston's Kendall Square, Accelerating Global Partnerships in AI Sleep Healthcare

* New office in Boston-Cambridge innovation hub to expand partnerships with healthcare and life sciences leaders * Supported through a Korea Health Industry Development Institute global expansion program * Strategic move expected to accelerate commercialization, clinical collaborations, and...

2026-04-28 19:00 3278

Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline

HONG KONG, April 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the company's first-in-class PD-1/VEGF bispecific antibody, has secured multiple authoritative updates and upgrades across first-line and later-line settings in the officia...

2026-04-28 16:07 3786

AHG Announces Initiation of World-Class, Proprietary Brain-Computer Interface R&D Program - Targeting the Next Frontier of Human Neurotechnology

QINGDAO, China, April 27, 2026 /PRNewswire/ -- Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the commencement of its next-generation, proprietary Brain-Computer Interface (BCI) technology research and development program. The Company is establishing the foundati...

2026-04-27 21:00 3577

Classys Emerges as a Global Leader in Medical Aesthetics Beyond K-Beauty, Highlighting 45% Growth, 50%+ Margins, and Recurring Revenue Model

– Operations in 80+ countries with over 45,000 installed platforms and 66% international revenue mix – Consumables account for 46% of revenue, with more than 5.5 million HIFU procedures performed annually worldwide – Accelerating growth through two strategic M&A transactions over the past two yea...

2026-04-27 21:00 4046

WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026

* Total Revenue Reached RMB 12.44 Billion; Revenue from Continuing Operations Up 39.4% YoY * Adjusted Non-IFRS Net Profit Up 71.7% YoY to RMB 4.60 Billion * Backlog for Continuing Operations Up 23.6% YoY to RMB 59.77 Billion SHANGHAI ,April 27, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 60...

2026-04-27 17:03 4273

The World's First Open-Source Medical Video LLM Released, Calling the Global Developer Community to Push It Further

SHANGHAI, April 24, 2026 /PRNewswire/ -- United Imaging Intelligence (UII) has unveiled uAI NEXUS MedVLM, a pioneering Medical Video Large Language Model that delivers unprecedented spatial and temporal precision in clinical environments. UII is fully open-sourcing the model and introducing a new...

2026-04-24 21:19 3758

Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE

* For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclinical candidate, jointly announced with the Emirates Drug Establishment (EDE), with the support of local partners including Abu Dhabi Investment Office (ADIO), the Department of Health Abu Dhabi (DoH)...

2026-04-24 21:00 2685

Miracell Demonstrates Cognition Impairment and Brain Function Improvement in Severe Alzheimer's Patients Using 'SMART M-CELL'-Based CD34+ Cell-Rich Autologous Blood Concentrate Therapy

* Study published in SCIE-indexed international journal Molecular Neurobiology * Three intravenous infusions at four-week intervals showed benefits in cognition, brain metabolism, and structural preservation SEOUL, South Korea, April 24, 2026 /PRNewswire/ -- Miracell, a stem cell-focused biotec...

2026-04-24 20:00 3230

CGBIO Receives FDA 510(k) Clearance for Patient-Specific Titanium Implant 'EASYMADE TI'

* Patient-specific titanium implant designed for cranial and craniofacial reconstruction * First Korean company to obtain FDA 510(k) clearance for a customized titanium implant in the U.S. market SEOUL, South Korea, April 24, 2026 /PRNewswire/ -- CGBIO (CEO: Hyunseung Yu) announced that its...

2026-04-24 20:00 2501

HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma

Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight TAIPEI and SHANGHAI and SAN FRANCISCO, April 24, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for immun...

2026-04-24 19:30 2629

WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival

CHENGDU, China, April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the structural completion and key equipment arrival at its microbial commercial manufacturing site in Chengdu, marking a...

2026-04-24 19:03 2778

CMUH and Partners Unveil Breakthrough Targeted Exosome Platform for Non-Invasive Spinal Cord Injury Repair

Developed by China Medical University Hospital, Ever Supreme International Biotechnology Co., Ltd. and SHINE OUT BIO TECHNOLOGY CO., LTD., the platform facilitates intravenous, lesion-targeted delivery of BDNF mRNA and improved motor coordination in preclinical models. TAICHUNG, April 24, 2026 /...

2026-04-24 14:58 2806

MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia

* Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).1,2 * De...

2026-04-23 15:00 3262
1234567 ... 257

Week's Top Stories